ClinicalTrials.gg
Active, not recruitingNCT05397496Updated Jul 28, 2026

Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies

A Phase 1 interventional study of PIT565 in B-cell Non-Hodgkin Lymphoma (B-NHL) and B-cell Acute Lymphoblastic Leukemia (B-ALL), sponsored by Novartis Pharmaceuticals. Active, not recruiting at 18 sites in 9 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
61
Allocation
Non-randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 398 studies in Lymphoma, B-Cell with a site in United States — 91 open to participants now, 157 under way, 12 of them phase 3. Lymphoma, B-Cell · United States.

Enrollment
120th of 380
61 · median 37
Started
2022
with 29 others
Phase 1
161 of 398
34 open now
Primary completion
2027-01
later than 47 of 156 live
Registered
295th of 398
by date
Lead sponsor
7 of 398
Novartis Pharmaceuticals

Among the 398 studies in Lymphoma, B-Cell with a site in United States, this one is the 120th largest by enrollment of the 380 interventional ones that give a count, is one of 30 that started in 2022, is one of 161 in phase 1, reaches primary completion later than 47 of the 156 other live ones, and was the 295th registered.

Lymphoma, B-Cell

885 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

91 of the 398 studies in Lymphoma, B-Cell with a site in United States are open now. Recruiting first, the newest first:

86 more — sign in →

All 91 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 129 (62%) set no upper age limit and 60 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 398 studies in Lymphoma, B-Cell with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, multicenter, phase I study, which primary objective is to characterize the safety and tolerability of PIT565 and to identify maximal tolerated doses (MTDs) and/or recommended doses (RDs), schedule and route of administration in relapsed and/or refractory B-cell Non-Hodgkin lymphoma (R/R B-NHL) and relapsed and/or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).

Read the detailed description

This is an open-label, multicenter, phase I study of PIT565 in patients with R/R B-NHL and R/R B-ALL.

The study comprises a dose escalation part of PIT565 in two independent groups (group A: R/R B-NHL and B: R/R B-ALL) and a dose expansion part in three independent groups (R/R large B-cell lymphoma (LBCL) randomized in 1:1 ratio to two RDs (A1 and A2), and R/R B-ALL (B1)).

During the dose escalation, the safety (including the dose-dose limiting toxicity (DLT) relationship) and tolerability of PIT565 will be assessed, and schedule(s), route(s) of administration and dose(s) will be identified for use in the expansion part based on the review of these data. The RD will also be guided by the available information on pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity. The dose escalation will be guided by an adaptive Bayesian logistic regression model (BLRM) following the Escalation with Overdose Control (EWOC) principle.

Different schedules and routes of administrations will be explored in the dose escalation groups.

The dose expansion will further explore the MTD(s) and/or RD(s) and the selected schedule(s) and route of administration(s) in the three patients' groups.

03

Conditions studied

  • B-cell Non-Hodgkin Lymphoma (B-NHL)
  • B-cell Acute Lymphoblastic Leukemia (B-ALL)

Keywords

  • Phase I
  • Trispecific antibody
  • Non-Hodgkin lymphoma
  • Acute Lymphoblastic Leukemia
  • PIT565
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed must be obtained prior to participation in the study.
  • Male or female patients ≥18 years of age at the date of signing the informed consent form
  • (ECOG) performance status ≤2

NHL patient population

  • or relapsed B-NHL
  • Must have relapsed after or failed to respond to at least two prior treatment therapies including an αCD20 monoclonal antibody containing chemotherapy combination regimen
  • Must have at least one bi-dimensionally measurable nodal lesion or one bi-dimensionally measurable extranodal lesion, as measured on positron emission tomography-computed tomography (PET/CT) scan

ALL patient population

  • Refractory or relapsed CD19-positive B-ALL
  • Morphologic disease in the bone marrow (≥ 5% blasts)

Exclusion criteria

Exclusion Criteria:

  • History of severe to any ingredient of the study treatment or its
  • to tocilizumab
  • History of ongoing, chronic or recurrent infectious disease, or evidence of tuberculosis infection
  • Malignant disease, other than that being treated in this study. Exceptions to this exclusion include the following: that were treated curatively and have not recurred within 2 years prior to study treatment; completely resected basal cell and squamous cell skin cancers, and completely resected carcinoma in situ of any type
  • Active central nervous system (CNS) involvement by malignancy or presence of symptomatic , or CNS metastases that require local CNS-directed therapy (such as radiotherapy or surgery), or increasing doses of within the 2 weeks prior to the start of study treatment
  • Active, known or suspected disease other than patients with vitiligo, residual hypothyroidism only requiring hormone replacement, psoriasis not requiring systemic treatment or conditions not expected to recur
  • Patients receiving systemic treatment with any medication

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    PIT565 Group A (dose escalation part)

    PIT565 in adult NHL patients for whom two or more lines of chemotherapy have failed and either having progressed (or relapsed) after autologous hematopoietic stem cell transplantation (HSCT), or being ineligible for or not consenting to the procedure

    Biological: PIT565

  • Experimental
    PIT565 Group B (dose escalation part)

    PIT565 in adult R/R ALL patients.

    Biological: PIT565

  • Experimental
    PIT565 Group A1 (dose expansion part)

    PIT565 Recommended dose 1 (RD1) in adult R/R large B-cell lymphoma (LBCL) (DLBCL, double/triple hit High-grade B-cell lymphoma (HGBCL), Primary mediastinal large B-cell lymphoma (PMBCL), Follicular lymphoma grade 3B (FL3B)) patients.

    Biological: PIT565

  • Experimental
    PIT565 Group A2 (dose expansion part)

    PIT565 RD2 in adult R/R LBCL (DLBCL, double/triple hit HGBCL, PMBCL, FL3B) patients.

    Biological: PIT565

  • Experimental
    PIT565 Group B1 (dose expansion part)

    PIT565 in adult R/R ALL patients.

    Biological: PIT565

Interventions

  • BiologicalPIT565

    Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection

06

What researchers measure

Primary outcomes

  1. Incidence and severity of Dose Limiting Toxicities (DLTs)

    Assessment of safety of study drug. A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value of CTCAE grade 3 or higher that occurs within the DLT evaluation period (28 days or 35 days depending on the schedule) and that is not primarily related to disease, disease progression, intercurrent illness, or concomitant medications with exceptions provided in the clinical protocol.

    Time frame: 28 days or 35 days, depending on the dosing schedule

  2. Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Assessment of safety of study drug.

    Time frame: 21 months

  3. Frequency of dose interruptions

    Assessment of tolerability of study drug

    Time frame: 21 months

  4. Frequency of dose reductions

    Assessment of tolerability of study drug

    Time frame: 21 months

  5. Dose intensities

    Assessment of tolerability of study drug Dose intensity is defined as the ratio of actual cumulative dose received and actual duration of exposure.

    Time frame: 21 months

Secondary outcomes

  1. Overall Response Rate (ORR)

    Evaluation of anti-tumor activity of PIT565 for Non-Hodgkin Lymphoma will be based on the Lugano Response Criteria Classification and anti-tumor activity of PIT565 for Acute Lymphoblastic Leukemia will be based on National Comprehensive Cancer Network (NCCN) 2018 v1 guidelines. Local investigator assessment will be used for analysis of efficacy endpoints.

    Time frame: 21 months

  2. Complete Response (CR) rate

    Evaluation of anti-tumor activity of PIT565 for Non-Hodgkin Lymphoma will be based on the Lugano Response Criteria Classification and anti-tumor activity of PIT565 for Acute Lymphoblastic Leukemia will be based on National Comprehensive Cancer Network (NCCN) 2018 v1 guidelines. Local investigator assessment will be used for analysis of efficacy endpoints.

    Time frame: 21 months

  3. Best Overall Response (BOR)

    Evaluation of anti-tumor activity of PIT565 for Non-Hodgkin Lymphoma will be based on the Lugano Response Criteria Classification and anti-tumor activity of PIT565 for Acute Lymphoblastic Leukemia will be based on National Comprehensive Cancer Network (NCCN) 2018 v1 guidelines. Local investigator assessment will be used for analysis of efficacy endpoints.

    Time frame: 21 months

  4. Duration Of Response (DOR)

    Evaluation of anti-tumor activity of PIT565 for Non-Hodgkin Lymphoma will be based on the Lugano Response Criteria Classification and anti-tumor activity of PIT565 for Acute Lymphoblastic Leukemia will be based on National Comprehensive Cancer Network (NCCN) 2018 v1 guidelines. Local investigator assessment will be used for analysis of efficacy endpoints.

    Time frame: 21 months

  5. Overall Survival (OS)

    Evaluation of anti-tumor activity of PIT565 for Non-Hodgkin Lymphoma will be based on the Lugano Response Criteria Classification and anti-tumor activity of PIT565 for Acute Lymphoblastic Leukemia will be based on National Comprehensive Cancer Network (NCCN) 2018 v1 guidelines. Local investigator assessment will be used for analysis of efficacy endpoints.

    Time frame: 33 months

  6. Progression Free Survival (PFS)

    Evaluation of anti-tumor activity of PIT565 for Non-Hodgkin Lymphoma will be based on the Lugano Response Criteria Classification Local investigator assessment will be used for analysis of efficacy endpoints.

    Time frame: 21 months

  7. Event-free survival (EFS)

    Evaluation of anti-tumor activity of PIT565 for Acute Lymphoblastic Leukemia will be based on National Comprehensive Cancer Network (NCCN) 2018 v1 guidelines. Local investigator assessment will be used for analysis of efficacy endpoints.

    Time frame: 21 months

  8. Maximum concentration of PIT565 (Cmax)

    Pharmacokinetics (PK) parameters will be determined using non-compartmental method(s)

    Time frame: 21 months

  9. Area Under the Curve of PIT565 (AUC)

    Pharmacokinetics (PK) parameters will be determined using non-compartmental method(s)

    Time frame: 21 months

  10. Trough concentration of PIT565 (C trough)

    Pharmacokinetics (PK) parameters will be determined using non-compartmental method(s)

    Time frame: 21 months

  11. Prevalence of Anti-drug antibodies (ADA) at baseline

    Assessment of anti-PIT565 antibodies in serum.

    Time frame: Baseline

  12. Incidence of Anti-drug antibodies (ADA) on treatment

    Assessment of anti-PIT565 antibodies in serum.

    Time frame: 21 months

07

Study locations

18 sites
  • University Of Miami
    Miami, Florida 33136, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • The University of Kansas Clinical Research Ctr
    Fairway, Kansas 66205, United States
  • Memorial Sloan Kettering Cancer Ctr
    New York, New York 10065, United States
  • Oregon Health Sciences University
    Portland, Oregon 97239, United States
  • Novartis Investigative Site
    Ghent, 9000, Belgium
  • Novartis Investigative Site
    Beijing, 100730, China
  • Novartis Investigative Site
    Shanghai, 200032, China
  • Novartis Investigative Site
    Tianjin, 300020, China
  • Novartis Investigative Site
    Créteil, 94010, France
  • Novartis Investigative Site
    Marseille, 13273, France
  • Novartis Investigative Site
    Tel Aviv, 6423906, Israel
  • Novartis Investigative Site
    Reggio Emilia, RE 42123, Italy
  • Novartis Investigative Site
    Kashiwa, Chiba 277-8577, Japan
  • Novartis Investigative Site
    Singapore, 119074, Singapore
  • Novartis Investigative Site
    Singapore, 169608, Singapore
  • Novartis Investigative Site
    Barcelona, 08035, Spain
  • Novartis Investigative Site
    Barcelona, 08036, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Jan 2027, 51 months after the start.

Of 90 industry-sponsored phase 1 interventional studies under Lymphoma, B-Cell, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 81. This study's planned 51 months is close to that.

Counting every sponsor, half of 207 studies reached it within 51 months; a quarter within 37 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2022
First posted
May 31, 2022
StartActual
Oct 3, 2022
Primary completionEst.
Jan 4, 2027
CompletionEst.
Jan 4, 2027
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05397496
Responsible party
Sponsor
First posted
May 31, 2022
Start date
Oct 3, 2022
Primary completion
Jan 4, 2027 (estimated)
Completion
Jan 4, 2027 (estimated)
Last update
Jul 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565

Start the discussion